CPS Overactive Bladder (OAB) Amendment (2015)

Member only benefit! AUA Guidelines provide a comprehensive and rigorous summary of evidence relating to a variety of disease conditions, providing an indispensable resource for urologic education. The Clinical Problem Solving (CPS) Protocols guideline-based Case Scenarios were designed to help maximize the impact of the guidelines. Overactive bladder (OAB) is a clinical diagnosis characterized by the presence of bothersome urinary symptoms. The International Continence Society (ICS) defines OAB as the presence of "urinary urgency, usually accompanied by frequency and nocturia, with or without urgency urinary incontinence, in the absence of UTI or other obvious pathology." Therefore, OAB symptoms consist of four components: urgency, frequency, nocturia and urgency incontinence. The OAB guideline was created to serve as a guide for all types of providers who evaluate and treat OAB patients, including those in general practice as well as those who specialize in various branches of medicine.

Target Audience

  • Urologists (Practicing; Recertification Candidates; International)
  • Residents

Learning Objectives

After completion of this activity, participants should be able to:

  1. Interpret and explain the appropriate diagnosis, prevention and treatment of the related guideline.
  2. Perform appropriate methods of evaluation and management according to the guideline.
  3. Analyze the risks and benefits for treatment according to the guideline.
  4. Integrate AUA guidelines into clinical practice.
Course summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Course opens: 
05/28/2015
Course expires: 
05/28/2018
Rating: 
0

Faculty
Faculty Disclosures
Harris Foster, Jr., MD: Astella: Scientific Study or Trial  
Alexander Gomelsky, MD: Nothing to disclose             
Deborah Lightner, MD: Urology/Elsevier: Health Publishing; Neurourology-Urodynamics: Health Publishing
Elspeth Marguerita McDougall, MD: Nothing to disclose
                                         
Planner Disclosures
Education Council
Gopal Badlani, MD: Lithotripsy Group: Piedmont Stone & Physician Discovery: Investment Interest; Society of University Urologist: Leadership Position; NIDDK: Leadership Position; Endourology Society: Other        
Timothy Charles Brand, MD: Nothing to disclose   
Peter Robert Carroll, MD, MPH: NIH: Scientific Study or Trial; Department of Defense: Scientific Study or Trial; Myriad Genetics: Scientific Study or Trial; Genomic Health: Scientific Study or Trial; AUA Update: Leadership Position; Medivation/Astellas: Consultant or Advisor
Sam S. Chang, MD: Astellas: Consultant or Advisor; NIH: Scientific Study or Trial; Cold Genesys, Inc.: Scientific Study or Trial; GLG: Consultant or Advisor; Bayer: Consultant or Advisor; Tolmar: Consultant or Advisor
Pat Fox Fulgham, MD: Urology Clinics of North Texas: Investment Interest
Matthew Thomas Gettman, MD: Nothing to disclose
Inderbir Singh Gill, MD, MCh: Hansen Medical: Investment Interest; EDAP: Consultant or Advisor; Mimic: Consultant or Advisor
Misop Han, MD: Nothing to disclose
David Alan Hatch, MD: Pfizer: Scientific Study or Trial
Christina Hernandez (AUA Staff): Nothing to disclose         
Douglas A. Husmann, MD: Nothing to disclose 
Mark L. Jordan, MD, FACS: Nothing to disclose          
Wes Kassouf, MD: Nothing to disclose          
Louis Koncz, PA-C: American Medical Systems: Meeting Participant or Lecturer
Tracey Lynn Krupski, MD: Nothing to disclose
Cheryl Taylore Lee, MD: Endo Pharmaceuticals: Scientific Study or Trial
Thomas Sean Lendvay, MD: Spi Surgical Inc.: Consultant or Advisor, Owner, Product Development; CSATS, Inc.: Consultant or Advisor, Investment Interest, Owner, Product Development
Yair Lotan, MD: Abbott: Scientific Study or Trial; Danone: Consultant or Advisor, Scientific Study or Trial; Cepheid: Scientific Study or Trial; Pacific Edge: Scientific Study or Trial; FKD: Scientific Study or Trial
Jill A. Macoska, PhD: Nothing to disclose
Elspeth Marguerita McDougall, MD: Nothing to disclose  
Manoj Monga, MD: Fortec: Other; Endourology Society: Leadership Position; Practical Reviews in Urology: Health Publishing
John Patrick Mulhall, MD: Association of Peyronie's Disease Advocates (APDA): Leadership Position; Pfizer: Scientific Study or Trial; Absorption Pharmaceuticals: Consultant or Advisor; AMS: Consultant or Advisor, Scientific Study or Trial; Lilly: Consultant or Advisor; Alliance for Fertility Preservation: Leadership Position; Coloplast: Scientific Study or Trial
Victor William Nitti, MD: Astellas: Health Publishing, Consultant or Advisor, Scientific Study or Trial; Allergan: Health Publishing, Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Coloplast: Health Publishing, Consultant or Advisor, Scientific Study or Trial; Serenity Pharmaceuticals: Consultant or Advisor, Investment Interest; American Medical Systems: Health Publishing, Consultant or Advisor, Scientific Study or Trial; Theracoat: Consultant or Advisor; Pneumoflex: Consultant or Advisor; Pfizer: Consultant or Advisor
Gail S. Prins, PhD: Nothing to disclose
Lee Richstone, MD: Nothing to disclose
Marianne D. Sadar, PhD: ESSA Pharma Inc.: Leadership Position, Consultant or Advisor, Investment Interest
Karl-Dietrich Sievert, MD, PhD: AMS: Meeting Participant or Lecturer; Karl Storz: Meeting Participant or Lecturer; Medtronics: Meeting Participant or Lecturer, Scientific Study or Trial; Allergen: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Neotract: Meeting Participant or Lecturer
Joseph A. Smith, Jr., MD: Nothing to disclose
Sheila Stark, PhD (AUA Staff): Nothing to disclose 
Sean Patrick Stroup, MD: Intuitive Surgical: Meeting Participant or Lecturer; NeoTract: Meeting Participant or Lecturer
Chandru P. Sundaram, MD: Journal of Endourology and Videourology: Leadership Position; Sonacare, Inc.: Scientific Study or Trial; OnTarget Inc: Scientific Study or Trial; IAUA: Leadership Position
Edouard John Trabulsi, MD: Nothing to disclose 
Paul Jacob Turek, MD: MandalMed: Leadership Position; Medical Board of California: Consultant or Advisor; HealthLoop.com: Consultant or Advisor, Investment Interest; Doximity, Inc.: Consultant or Advisor, Investment Interest; Fertility Planit, Inc.: Consultant or Advisor, Investment Interest; Episona, Inc: Consultant or Advisor; BioQuiddity, Inc.: Consultant or Advisor, Investment Interest; Essential Beginnings, Inc: Leadership Position, Investment Interest, Owner, Product Development 
Jennifer Yates, MD: Nothing to disclose

Method of Participation

Learners will participate in this interactive online educational activity by completing a pre-test, reading the AUA Guideline, complete the slides and case studies, answering multiple choice questions, examining patient tools and resources and completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the posttest, passing with 80% accuracy and submit the program evaluation.

Estimated time to complete each activity: 2.0 hours

Release Date: May, 2015
Expiration Date: May, 2018

AUA Disclosure Policy

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) participating in an educational activity provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Resolution of Identified Conflict of Interest

All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

· Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup

· Limit content to evidence with no recommendations

· Introduction of a debate format with an unbiased moderator (point-counterpoint)

· Inclusion of moderated panel discussion

· Publication of a parallel or rebuttal article for an article that is felt to be biased

· Limit equipment representatives to providing logistics and operation support only in procedural demonstrations

· Divestiture of the relationship by faculty

Faculty

Faculty Disclosures

Harris Foster, Jr., MD: Astella: Scientific Study or Trial

Alexander Gomelsky, MD: Nothing to disclose

Deborah Lightner, MD: Urology/Elsevier: Health Publishing; Neurourology-Urodynamics: Health Publishing

Elspeth Marguerita McDougall, MD: Nothing to disclose

Planner Disclosures

Education Council

Gopal Badlani, MD: Lithotripsy Group: Piedmont Stone & Physician Discovery: Investment Interest; Society of University Urologist: Leadership Position; NIDDK: Leadership Position; Endourology Society: Other

Timothy Charles Brand, MD: Nothing to disclose

Peter Robert Carroll, MD, MPH: NIH: Scientific Study or Trial; Department of Defense: Scientific Study or Trial; Myriad Genetics: Scientific Study or Trial; Genomic Health: Scientific Study or Trial; AUA Update: Leadership Position; Medivation/Astellas: Consultant or Advisor

Sam S. Chang, MD: Astellas: Consultant or Advisor; NIH: Scientific Study or Trial; Cold Genesys, Inc.: Scientific Study or Trial; GLG: Consultant or Advisor; Bayer: Consultant or Advisor; Tolmar: Consultant or Advisor

Pat Fox Fulgham, MD: Urology Clinics of North Texas: Investment Interest

Matthew Thomas Gettman, MD: Nothing to disclose

Inderbir Singh Gill, MD, MCh: Hansen Medical: Investment Interest; EDAP: Consultant or Advisor; Mimic: Consultant or Advisor

Misop Han, MD: Nothing to disclose

David Alan Hatch, MD: Pfizer: Scientific Study or Trial

Christina Hernandez (AUA Staff): Nothing to disclose

Douglas A. Husmann, MD: Nothing to disclose

Mark L. Jordan, MD, FACS: Nothing to disclose

Wes Kassouf, MD: Nothing to disclose

Louis Koncz, PA-C: American Medical Systems: Meeting Participant or Lecturer

Tracey Lynn Krupski, MD: Nothing to disclose

Cheryl Taylore Lee, MD: Endo Pharmaceuticals: Scientific Study or Trial

Thomas Sean Lendvay, MD: Spi Surgical Inc.: Consultant or Advisor, Owner, Product Development; CSATS, Inc.: Consultant or Advisor, Investment Interest, Owner, Product Development

Yair Lotan, MD: Abbott: Scientific Study or Trial; Danone: Consultant or Advisor, Scientific Study or Trial; Cepheid: Scientific Study or Trial; Pacific Edge: Scientific Study or Trial; FKD: Scientific Study or Trial

Jill A. Macoska, PhD: Nothing to disclose

Elspeth Marguerita McDougall, MD: Nothing to disclose

Manoj Monga, MD: Fortec: Other; Endourology Society: Leadership Position; Practical Reviews in Urology: Health Publishing

John Patrick Mulhall, MD: Association of Peyronie's Disease Advocates (APDA): Leadership Position; Pfizer: Scientific Study or Trial; Absorption Pharmaceuticals: Consultant or Advisor; AMS: Consultant or Advisor, Scientific Study or Trial; Lilly: Consultant or Advisor; Alliance for Fertility Preservation: Leadership Position; Coloplast: Scientific Study or Trial

Victor William Nitti, MD: Astellas: Health Publishing, Consultant or Advisor, Scientific Study or Trial; Allergan: Health Publishing, Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Coloplast: Health Publishing, Consultant or Advisor, Scientific Study or Trial; Serenity Pharmaceuticals: Consultant or Advisor, Investment Interest; American Medical Systems: Health Publishing, Consultant or Advisor, Scientific Study or Trial; Theracoat: Consultant or Advisor; Pneumoflex: Consultant or Advisor; Pfizer: Consultant or Advisor

Gail S. Prins, PhD: Nothing to disclose

Lee Richstone, MD: Nothing to disclose

Marianne D. Sadar, PhD: ESSA Pharma Inc.: Leadership Position, Consultant or Advisor, Investment Interest

Karl-Dietrich Sievert, MD, PhD: AMS: Meeting Participant or Lecturer; Karl Storz: Meeting Participant or Lecturer; Medtronics: Meeting Participant or Lecturer, Scientific Study or Trial; Allergen: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Neotract: Meeting Participant or Lecturer

Joseph A. Smith, Jr., MD: Nothing to disclose

Sheila Stark, PhD (AUA Staff): Nothing to disclose

Sean Patrick Stroup, MD: Intuitive Surgical: Meeting Participant or Lecturer; NeoTract: Meeting Participant or Lecturer

Chandru P. Sundaram, MD: Journal of Endourology and Videourology: Leadership Position; Sonacare, Inc.: Scientific Study or Trial; OnTarget Inc: Scientific Study or Trial; IAUA: Leadership Position

Edouard John Trabulsi, MD: Nothing to disclose

Paul Jacob Turek, MD: MandalMed: Leadership Position; Medical Board of California: Consultant or Advisor; HealthLoop.com: Consultant or Advisor, Investment Interest; Doximity, Inc.: Consultant or Advisor, Investment Interest; Fertility Planit, Inc.: Consultant or Advisor, Investment Interest; Episona, Inc: Consultant or Advisor; BioQuiddity, Inc.: Consultant or Advisor, Investment Interest; Essential Beginnings, Inc: Leadership Position, Investment Interest, Owner, Product Development

Jennifer Yates, MD: Nothing to disclose

Accreditation Statement

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The American Urological Association designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Evidence-Based Content

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

Off-label or Unapproved Use of Drugs or Devices

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the product prescribing information for full disclosure of approved uses.

Disclaimer

The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Reproduction Permission

Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

AUA Privacy and Confidentiality Policy

www.auanet.org/education/confidentiality-statement.cfm

Contact Information

American Urological Association

Office of Education

1000 Corporate Blvd

Linthicum, MD 21090

Toll Free (U.S. only): 1-866-RING AUA (1-866-746-4282)

Phone: 410-689-3700

Fax: 410-689-3800

CME Information

For all inquiries regarding CME credit email: cme@AUAnet.org

Available Credit

  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation

Accreditation Period

Course opens: 
05/28/2015
Course expires: 
05/28/2018
Please login or register to take this course.